Downloads: 775

Files in This Item:
File Description SizeFormat 
s12929-017-0329-9.pdf842.2 kBAdobe PDFView/Open
Title: Cancer immunotherapies targeting the PD-1 signaling pathway
Authors: Iwai, Yoshiko
Hamanishi, Junzo  kyouindb  KAKEN_id  orcid (unconfirmed)
Chamoto, Kenji  kyouindb  KAKEN_id
Honjo, Tasuku
Author's alias: 濱西, 潤三
茶本, 健司
本庶, 佑
Keywords: PD-1
Cancer immunotherapy
Immune checkpoint
Issue Date: 4-Apr-2017
Publisher: Springer Nature
Journal title: Journal of Biomedical Science
Volume: 24
Thesis number: 26
Abstract: Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.
Rights: © The Author(s). 2017 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
DOI(Published Version): 10.1186/s12929-017-0329-9
PubMed ID: 28376884
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.